Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $9.77 in the prior trading day, Enfusion Inc (NYSE: ENFN) closed at $9.26, down -5.22%. In other words, the price has decreased by -$5.22 from its previous closing price. On the day, 0.59 million shares were traded. ENFN stock price reached its highest trading level at $9.76 during the session, while it also had its lowest trading level at $8.87.
Ratios:
Our goal is to gain a better understanding of ENFN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 23.64 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 56.82. For the most recent quarter (mrq), Quick Ratio is recorded 3.44 and its Current Ratio is at 3.44. In the meantime, Its Debt-to-Equity ratio is 0.29 whereas as Long-Term Debt/Eq ratio is at 0.21.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 28, 2024, Downgraded its rating to Sell and sets its target price to $8 from $9 previously.
On January 30, 2024, JP Morgan Downgraded its rating to Underweight which previously was Neutral and also lowered its target price recommendation from $11 to $9.
On November 07, 2023, UBS started tracking the stock assigning a Neutral rating and target price of $9.UBS initiated its Neutral rating on November 07, 2023, with a $9 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 29 ’24 when Campobasso Matthew sold 108 shares for $8.73 per share. The transaction valued at 943 led to the insider holds 30,840 shares of the business.
Gutowski Valeria sold 27 shares of ENFN for $236 on Feb 29 ’24. The Chief Accounting Officer now owns 17,570 shares after completing the transaction at $8.73 per share. On Jan 10 ’24, another insider, Somers Deirdre, who serves as the Director of the company, sold 1,770 shares for $8.65 each. As a result, the insider received 15,310 and left with 34,471 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ENFN now has a Market Capitalization of 887868224 and an Enterprise Value of 881690112. As of this moment, Enfusion’s Price-to-Earnings (P/E) ratio for their current fiscal year is 191.32, and their Forward P/E ratio for the next fiscal year is 27.47. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.82 while its Price-to-Book (P/B) ratio in mrq is 15.24. Its current Enterprise Value per Revenue stands at 5.052 whereas that against EBITDA is 47.569.
Stock Price History:
Over the past 52 weeks, ENFN has reached a high of $11.56, while it has fallen to a 52-week low of $7.37. The 50-Day Moving Average of the stock is 0.64%, while the 200-Day Moving Average is calculated to be 1.75%.
Shares Statistics:
The stock has traded on average 416.94K shares per day over the past 3-months and 283620 shares per day over the last 10 days, according to various share statistics. A total of 88.33M shares are outstanding, with a floating share count of 47.12M. Insiders hold about 48.15% of the company’s shares, while institutions hold 59.03% stake in the company. Shares short for ENFN as of 1713139200 were 2173236 with a Short Ratio of 5.21, compared to 1710460800 on 3019732. Therefore, it implies a Short% of Shares Outstanding of 2173236 and a Short% of Float of 4.5300003.
